Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment
The hypoxia-inducible factor-1α (HIF-1α) plays a key role in facilitating the adaptation of cells to hypoxia, profoundly influencing the immune vascular microenvironment (IVM) and immunotherapy outcomes. HIF-1α-mediated tumor hypoxia drives angiogenesis, immune suppression, and extracellular matrix...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549276/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087134068015104 |
|---|---|
| author | Shaoyan Shi Xuehai Ou Chao Liu Hao Wen Jiang Ke |
| author_facet | Shaoyan Shi Xuehai Ou Chao Liu Hao Wen Jiang Ke |
| author_sort | Shaoyan Shi |
| collection | DOAJ |
| description | The hypoxia-inducible factor-1α (HIF-1α) plays a key role in facilitating the adaptation of cells to hypoxia, profoundly influencing the immune vascular microenvironment (IVM) and immunotherapy outcomes. HIF-1α-mediated tumor hypoxia drives angiogenesis, immune suppression, and extracellular matrix remodeling, creating an environment that promotes tumor progression and resistance to immunotherapies. HIF-1α regulates critical pathways, including the expression of vascular endothelial growth factor and immune checkpoint upregulation, leading to tumor-infiltrating lymphocyte dysfunction and recruitment of immunosuppressive cells like regulatory T cells and myeloid-derived suppressor cells. These alterations reduce the efficacy of checkpoint inhibitors and other immunotherapies. Recent studies highlight therapeutic strategies that target HIF-1α, such as the use of pharmacological inhibitors, gene editing techniques, and hypoxia-modulating treatments, which show promise in enhancing responses to immunotherapy. This review explores the molecular mechanisms of action of HIF-1α in IVM, its impact on immunotherapy resistance, as well as potential interventions, emphasizing the need for innovative approaches to circumvent hypoxia-driven immunosuppression in cancer therapy. |
| format | Article |
| id | doaj-art-7689ce1466ed4913be05885ca5934760 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7689ce1466ed4913be05885ca59347602025-02-06T07:10:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15492761549276Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironmentShaoyan ShiXuehai OuChao LiuHao WenJiang KeThe hypoxia-inducible factor-1α (HIF-1α) plays a key role in facilitating the adaptation of cells to hypoxia, profoundly influencing the immune vascular microenvironment (IVM) and immunotherapy outcomes. HIF-1α-mediated tumor hypoxia drives angiogenesis, immune suppression, and extracellular matrix remodeling, creating an environment that promotes tumor progression and resistance to immunotherapies. HIF-1α regulates critical pathways, including the expression of vascular endothelial growth factor and immune checkpoint upregulation, leading to tumor-infiltrating lymphocyte dysfunction and recruitment of immunosuppressive cells like regulatory T cells and myeloid-derived suppressor cells. These alterations reduce the efficacy of checkpoint inhibitors and other immunotherapies. Recent studies highlight therapeutic strategies that target HIF-1α, such as the use of pharmacological inhibitors, gene editing techniques, and hypoxia-modulating treatments, which show promise in enhancing responses to immunotherapy. This review explores the molecular mechanisms of action of HIF-1α in IVM, its impact on immunotherapy resistance, as well as potential interventions, emphasizing the need for innovative approaches to circumvent hypoxia-driven immunosuppression in cancer therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549276/fullHIF-1 αVEGFimmune vascular microenvironmentimmunotherapy resistancepersonalized cancer therapymachine learning HIF-1a |
| spellingShingle | Shaoyan Shi Xuehai Ou Chao Liu Hao Wen Jiang Ke Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment Frontiers in Immunology HIF-1 α VEGF immune vascular microenvironment immunotherapy resistance personalized cancer therapy machine learning HIF-1a |
| title | Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment |
| title_full | Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment |
| title_fullStr | Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment |
| title_full_unstemmed | Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment |
| title_short | Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment |
| title_sort | research progress of hif 1a on immunotherapy outcomes in immune vascular microenvironment |
| topic | HIF-1 α VEGF immune vascular microenvironment immunotherapy resistance personalized cancer therapy machine learning HIF-1a |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549276/full |
| work_keys_str_mv | AT shaoyanshi researchprogressofhif1aonimmunotherapyoutcomesinimmunevascularmicroenvironment AT xuehaiou researchprogressofhif1aonimmunotherapyoutcomesinimmunevascularmicroenvironment AT chaoliu researchprogressofhif1aonimmunotherapyoutcomesinimmunevascularmicroenvironment AT haowen researchprogressofhif1aonimmunotherapyoutcomesinimmunevascularmicroenvironment AT jiangke researchprogressofhif1aonimmunotherapyoutcomesinimmunevascularmicroenvironment |